Targeting angiogenesis in melanoma: prospects for the future

Area of Science:

• Oncology
• Melanoma Research
• Vascular Biology

Background:

• Angiogenesis is a validated therapeutic target in melanoma.
• Several angiogenesis inhibitors are under investigation in clinical trials for melanoma.
• Bevacizumab, an anti-vascular endothelial growth factor antibody, showed a trend towards survival benefit when combined with chemotherapy in a Phase II trial.

Purpose of the Study:

• To evaluate the clinical benefit of angiogenesis inhibitors in melanoma.
• To explore the role of translational endpoints in identifying predictive biomarkers.
• To improve the understanding of the mechanism of action and side effects of angiogenesis inhibitors.

Main Methods:

• Review of preclinical and clinical studies on angiogenesis inhibitors in melanoma.
• Analysis of a randomized Phase II trial combining bevacizumab with chemotherapy.
• Emphasis on the importance of translational endpoints in ongoing and future clinical trials.

Main Results:

• A non-significant trend in survival gain was observed in a Phase II trial combining bevacizumab with chemotherapy.
• Larger Phase III studies are necessary to confirm the clinical benefit of angiogenesis inhibitors.
• Translational endpoints are crucial for biomarker discovery and understanding treatment response.

Conclusions:

• Angiogenesis inhibitors represent a promising therapeutic strategy for melanoma.
• Further large-scale clinical trials are required to establish efficacy.
• Integrating translational research is essential for advancing melanoma treatment and developing next-generation therapies.